Renaissance Technologies's ANIP Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 272,902 shares of ANI Pharmaceuticals, Inc. (ANIP) worth $25 M, representing 0.03% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in ANIP, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 144,515 shares. Largest reduction occurred in Q2 2025, reducing 91,115 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's ANI Pharmaceuticals (ANIP) Holding Value Over Time
Track share changes against reported price movement
Quarterly ANI Pharmaceuticals (ANIP) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +117,702 | New Buy | 117,702 | $34.44 |
| Q3 2014 | -89,300 | Reduce 75.87% | 28,402 | $28.27 |
| Q4 2014 | +37,600 | Add 132.39% | 66,002 | $56.39 |
| Q1 2015 | -11,300 | Reduce 17.12% | 54,702 | $62.56 |
| Q2 2015 | -54,702 | Sold Out | 54,702 | $0.00 |
| Q2 2016 | +73,900 | New Buy | 73,900 | $55.82 |
| Q3 2016 | +117,000 | Add 158.32% | 190,900 | $66.35 |
| Q4 2016 | +41,800 | Add 21.90% | 232,700 | $60.62 |
| Q1 2017 | +45,300 | Add 19.47% | 278,000 | $49.51 |
| Q2 2017 | +19,400 | Add 6.98% | 297,400 | $46.80 |
| Q3 2017 | -7,100 | Reduce 2.39% | 290,300 | $52.49 |
| Q4 2017 | -57,000 | Reduce 19.63% | 233,300 | $64.45 |
| Q1 2018 | -57,600 | Reduce 24.69% | 175,700 | $58.22 |
| Q2 2018 | -2,400 | Reduce 1.37% | 173,300 | $66.80 |
| Q3 2018 | +5,100 | Add 2.94% | 178,400 | $56.54 |
| Q4 2018 | -9,000 | Reduce 5.04% | 169,400 | $45.02 |
| Q1 2019 | +29,800 | Add 17.59% | 199,200 | $70.54 |
| Q2 2019 | +88,900 | Add 44.63% | 288,100 | $82.20 |
| Q3 2019 | +45,100 | Add 15.65% | 333,200 | $72.88 |
| Q4 2019 | -67,300 | Reduce 20.20% | 265,900 | $61.67 |
| Q1 2020 | -3,600 | Reduce 1.35% | 262,300 | $40.74 |
| Q2 2020 | -88,900 | Reduce 33.89% | 173,400 | $32.34 |
| Q3 2020 | -30,398 | Reduce 17.53% | 143,002 | $28.21 |
| Q4 2020 | +13,702 | Add 9.58% | 156,704 | $29.04 |
| Q1 2021 | -41,502 | Reduce 26.48% | 115,202 | $36.14 |
| Q2 2021 | -47,823 | Reduce 41.51% | 67,379 | $35.06 |
| Q3 2021 | -9,079 | Reduce 13.47% | 58,300 | $32.81 |
| Q4 2021 | +40,202 | Add 68.96% | 98,502 | $46.08 |
| Q1 2022 | -9,900 | Reduce 10.05% | 88,602 | $28.11 |
| Q2 2022 | -88,602 | Sold Out | 88,602 | $0.00 |
| Q2 2023 | +61,302 | New Buy | 61,302 | $0.05 |
| Q3 2023 | -21,700 | Reduce 35.40% | 39,602 | $58.05 |
| Q4 2023 | +55,997 | Add 141.40% | 95,599 | $55.14 |
| Q1 2024 | +40,303 | Add 42.16% | 135,902 | $69.13 |
| Q2 2024 | +20,900 | Add 15.38% | 156,802 | $63.68 |
| Q3 2024 | +88,300 | Add 56.31% | 245,102 | $59.66 |
| Q4 2024 | -69,302 | Reduce 28.27% | 175,800 | $55.28 |
| Q1 2025 | +43,702 | Add 24.86% | 219,502 | $66.95 |
| Q2 2025 | -91,115 | Reduce 41.51% | 128,387 | $65.25 |
| Q3 2025 | +144,515 | Add 112.56% | 272,902 | $91.60 |
Renaissance Technologies's ANI Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased ANI Pharmaceuticals, Inc. (ANIP) in Q2 2014, acquiring 117,702 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held ANI Pharmaceuticals, Inc. (ANIP) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to ANI Pharmaceuticals, Inc. (ANIP) was in Q3 2025, adding 272,902 shares worth $25 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 272,902 shares of ANI Pharmaceuticals, Inc. (ANIP), valued at approximately $25 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ANI Pharmaceuticals, Inc. (ANIP) represents approximately 0.03% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in ANI Pharmaceuticals, Inc. (ANIP) was 333,200 shares, as reported at the end of Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.